PML (Progressive Multifocal Leukoencephalopathy) - Cleveland Clinic Progressive multifocal leukoencephalopathy (PML) is a rare brain infection that affects the substance in your brain that protects nerve cells PML gets worse over time and may lead to neurological disabilities
Progressive Multifocal Leukoencephalopathy | National Institute of . . . Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection (polyomavirus JC) that targets cells that make myelin—the material that insulates nerve cells (neurons)
Progressive multifocal leukoencephalopathy - Wikipedia PML is a demyelinating disease, in which the myelin sheath covering the axons of nerve cells is gradually destroyed, impairing the transmission of nerve impulses
Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML) - Learn about the causes, symptoms, diagnosis treatment from the Merck Manuals - Medical Consumer Version
Progressive Multifocal Leukoencephalopathy - WebMD Learn about progressive multifocal leukoencephalopathy (PML), its symptoms, causes, and treatments Understand how this disease impacts the brain's white matter
Progressive Multifocal Leukoencephalopathy (PML) - Rush Progressive multifocal leukoencephalopathy, or PML, is a rare, life-threatening infectious disease of the brain PML is caused by the reactivation of a common virus, polyomavirus JC, that infects and destroys parts of the brain
Progressive Multifocal Leukoencephalopathy | Neurology Gorelik L, Reid C, Testa M, et al Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity
PML Virus: Symptoms, Risk Factors, and More - Healthline What is the PML virus? PML stands for progressive multifocal leukoencephalopathy It’s an aggressive viral disease of the central nervous system The virus attacks cells that make myelin
International Consensus Classification of Myeloid Neoplasms and Acute . . . The WHO fourth edition and revised fourth edition classifications included 3 specific categories of AML (other than pure erythroid leukemia) that defined AML without regard to myeloblast percentage in the appropriate clinical setting: AML with t (8;21) (q22;q22 1) RUNX1:: RUNX1T1, AML with inv (16) (p13 1q22) or t (16;16) (p13 1;q22) CBFB:: MYH11, and acute promyelocytic leukemia with t (15;17) (q24;q21) PML:: RARA